ES2563091T3 - Polipéptidos modificados genéticamente que tienen duración de acción potenciada - Google Patents

Polipéptidos modificados genéticamente que tienen duración de acción potenciada Download PDF

Info

Publication number
ES2563091T3
ES2563091T3 ES11767876.3T ES11767876T ES2563091T3 ES 2563091 T3 ES2563091 T3 ES 2563091T3 ES 11767876 T ES11767876 T ES 11767876T ES 2563091 T3 ES2563091 T3 ES 2563091T3
Authority
ES
Spain
Prior art keywords
genetically modified
sequence
action
modified polypeptides
enhanced duration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11767876.3T
Other languages
English (en)
Inventor
Mary Erickson
David C. Litzinger
Soumitra S. Ghosh
Zijian Guo
Chengzao Sun
Christopher J. Soares
Manoj P. SAMANT
Odile E. Levy
Lala MAMEDOVA
Swetha NERAVETLA
Abhinandini Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44786115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2563091(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2563091T3 publication Critical patent/ES2563091T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)

Abstract

Un polipéptido modificado genéticamente que comprende: una secuencia de polipéptido de dominio de unión a albúmina (ABD) que comprende la secuencia de aminoácidos expuesta en SEC ID Nº: 35, y una primera secuencia de dominio de hormona peptídica (HD1) que comprende la secuencia de aminoácidos expuesta en SEC ID Nº: 3.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
Se contemplan específicamente compuestos de las secuencias anteriores en los que está ausente cualquier metionina N terminal. La metionina N terminal puede estar presente principalmente como una conveniencia para expresión bacteriana. Sin embargo, los péptidos modificados genéticamente de la presente invención pueden expresarse en una célula hospedadora eucariota (por ejemplo levadura (por ejemplo Pichia), mamífero, baculovirus)
5 u otra célula hospedadora que tiene procesamiento proteolítico N terminal postraduccional para producir un aminoácido N terminal como se encuentra en un homólogo peptídico maduro de origen natural de la secuencia de hormona o ABD deseada, es decir sin la metionina añadida u otra secuencia líder. Como alternativa, una secuencia N terminal usada para expresión y/o secreción (e incluso purificación) puede ser una que pueda retirarse postraduccionalmente, por ejemplo mediante el uso de una proteasa tal como TEV.
10 Los compuestos polipeptídicos modificados genéticamente adicionales contemplados en el presente documento, que tienen una diversidad de componentes HD1, L1 y ABD, incluyen los compuestos que tienen la estructura de cualquiera de los polipéptidos modificados genéticamente de las tablas y los listados del presente documento, incluyendo los desvelados en la Tabla 3B a continuación.
15 Tabla 3B. Polipéptidos modificados genéticamente ejemplares seleccionados
Secuencia
imagen21
imagen22
imagen23
imagen24
22
Secuencia
imagen25
imagen26
23
Secuencia
imagen27
imagen28
24
Secuencia
imagen29
imagen30
25
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59

Claims (1)

  1. imagen1
    imagen2
ES11767876.3T 2010-09-28 2011-09-28 Polipéptidos modificados genéticamente que tienen duración de acción potenciada Active ES2563091T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38739110P 2010-09-28 2010-09-28
US387391P 2010-09-28
US42208510P 2010-12-10 2010-12-10
US422085P 2010-12-10
PCT/US2011/053770 WO2012050923A2 (en) 2010-09-28 2011-09-28 Engineered polypeptides having enhanced duration of action

Publications (1)

Publication Number Publication Date
ES2563091T3 true ES2563091T3 (es) 2016-03-10

Family

ID=44786115

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11767876.3T Active ES2563091T3 (es) 2010-09-28 2011-09-28 Polipéptidos modificados genéticamente que tienen duración de acción potenciada

Country Status (11)

Country Link
US (2) US9593154B2 (es)
EP (2) EP3028720A1 (es)
JP (1) JP6121330B2 (es)
CN (2) CN103370083B (es)
BR (1) BR112013007442A2 (es)
CA (1) CA2812951A1 (es)
EA (1) EA201390450A1 (es)
ES (1) ES2563091T3 (es)
HK (2) HK1188710A1 (es)
MX (1) MX345245B (es)
WO (1) WO2012050923A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103370083B (zh) * 2010-09-28 2016-11-16 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
EP3241558B1 (en) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
US20160009767A9 (en) * 2012-03-28 2016-01-14 Affibody Ab Oral administration
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
KR20170068553A (ko) 2014-10-14 2017-06-19 아르모 바이오사이언시스 인코포레이티드 인터류킨-15 조성물 및 이의 용도
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
RU2721949C2 (ru) 2015-09-22 2020-05-25 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модифицированные цитотоксины и их терапевтическое применение
DK3393496T3 (en) 2015-12-23 2023-11-13 Univ Johns Hopkins Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
KR102460198B1 (ko) * 2016-03-10 2022-10-31 메디뮨 리미티드 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
CN115925951B (zh) * 2022-11-30 2024-05-24 上海交通大学医学院附属仁济医院 Cd70特异性诊疗一体化分子影像探针的制备方法及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
US6326468B1 (en) 1997-06-13 2001-12-04 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
AU756836B2 (en) 1997-11-14 2003-01-23 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
DE60021166T3 (de) 1999-01-14 2019-08-22 Amylin Pharmaceuticals, Llc Neue exendin agonist formulierungen und deren verabreichung
AU770712B2 (en) 1999-01-14 2004-02-26 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
PL377591A1 (pl) 2002-10-02 2006-02-06 Zealand Pharma A/S Stabilizowane związki eksendyny-4
EP2233497A3 (en) 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
PT1960422E (pt) * 2005-11-28 2012-08-16 Univ Pennsylvania Análogos de compstatina potentes
EP1976873A2 (en) 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
JP2009538824A (ja) 2006-03-31 2009-11-12 アミリン・ファーマシューティカルズ，インコーポレイテッド 精神疾患及び障害治療用アミリン及びアミリンアゴニスト
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
KR20090031368A (ko) 2006-05-26 2009-03-25 아밀린 파마슈티칼스, 인크. 울혈성 심부전 치료용 조성물 및 방법
EP2046820B1 (en) * 2006-08-01 2010-10-20 Pieris AG Muteins of tear lipocalin and methods for obtaining the same
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009003340A (ja) 2007-06-25 2009-01-08 Oki Data Corp 画像形成装置
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2190863B1 (en) * 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
SG189682A1 (en) * 2008-03-31 2013-05-31 Glaxo Group Ltd Drug fusions and conjugates
EP2288918A1 (en) 2008-05-23 2011-03-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist bioassays
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
PE20120170A1 (es) * 2009-02-19 2012-03-21 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas
EP2413955A4 (en) 2009-04-01 2012-12-26 Amylin Pharmaceuticals Inc AGONIST COMPOUNDS OF GLP-1 RECEPTORS HAVING CONFORMATIONAL CONSTRAINTS AT THEIR N-TERMINAL END
CN103370083B (zh) * 2010-09-28 2016-11-16 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides

Also Published As

Publication number Publication date
HK1225307A1 (zh) 2017-09-08
MX2013003481A (es) 2013-10-25
BR112013007442A2 (pt) 2019-09-24
WO2012050923A2 (en) 2012-04-19
EA201390450A1 (ru) 2013-07-30
US20170114114A1 (en) 2017-04-27
EP3028720A1 (en) 2016-06-08
CN103370083B (zh) 2016-11-16
CA2812951A1 (en) 2012-04-19
HK1188710A1 (zh) 2014-05-16
EP2621538B1 (en) 2015-12-16
EP2621538A2 (en) 2013-08-07
MX345245B (es) 2017-01-23
CN103370083A (zh) 2013-10-23
JP6121330B2 (ja) 2017-04-26
WO2012050923A3 (en) 2012-07-19
CN106986940A (zh) 2017-07-28
JP2013545724A (ja) 2013-12-26
US20140107019A1 (en) 2014-04-17
US9593154B2 (en) 2017-03-14

Similar Documents

Publication Publication Date Title
ES2563091T3 (es) Polipéptidos modificados genéticamente que tienen duración de acción potenciada
ES2600879T3 (es) Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
ES2509883T3 (es) Antagonistas de glucagón
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
DOP2009000194A (es) Glucagon/co-agonistas receptores de glp-1
DOP2021000197A (es) Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea
AR072160A1 (es) Co-agonistas del receptor de glucagon/glp-1
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
CR10591A (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
PE20240686A1 (es) Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20191716A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
ECSP20070185A (es) Análogos novedosos de glp-1
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
AR070491A1 (es) Variante de enzima lipolitica con estabilidad aumentada y polinucleotidos que la codifican
JP2015524403A5 (es)
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
EA200702012A1 (ru) Пептиды механо-фактора роста и их применение
RS54422B1 (en) APOPTOSIS INHIBITORS AND THEIR USES
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso